French Office REITs Stock News

Nanobiotix (ENXTPA:NANO) is back in focus after the FDA accepted a protocol amendment to the pivotal Phase 3 NANORAY-312 study of JNJ-1900 (NBTXR3) in head and neck cancer. See our latest analysis for Nanobiotix. The FDA news has landed on a stock that has already been on a powerful run, with a 30 day share price return of 42.58% and a 90 day move of 105.69%. The 1 year total shareholder return is very large at more than 10x and suggests momentum has been building for some time. If this kind...

Wondering if DBV Technologies at €3.40 is still priced for a turnaround or already baking in the story? This article walks through what the current share price could imply about value. The stock has returned 4.3% year to date and 90.4% over the past year, although the last 7 days and 30 days show declines of 6.2% and 6.6% respectively. Recent coverage has focused on DBV Technologies as a higher risk biotech with a history that includes a 67.5% share price decline over five years, set against...

How has L'Air Liquide (ENXTPA:AI) stock been performing recently? L'Air Liquide (ENXTPA:AI) stock has moved lower over the past week and month, with 7-day and 1-month returns of a 4.3% decline and a 4.5% decline, while the past 3 months show a 4.4% gain. See our latest analysis for L'Air Liquide. Short term momentum has cooled for L'Air Liquide, with recent share price returns softer over the past month. The year to date share price return of 10.14% sits against a 1 year total shareholder...

Why BNP Paribas (ENXTPA:BNP) is Back on Investors’ Radar Recent share performance has put BNP Paribas (ENXTPA:BNP) back in focus for many investors, with the stock showing mixed short term moves alongside solid longer term total returns over the past year. See our latest analysis for BNP Paribas. At a share price of €91.55, BNP Paribas has seen a 1.8% one day share price decline but still carries an 11.8% year to date share price return and a 30.0% one year total shareholder return. This...

ABIVAX Société Anonyme (ENXTPA:ABVX) completed a $90 million transaction to repurchase all existing royalty certificates. The repurchased royalty certificates are being cancelled, removing future royalty obligations linked to them. This transaction simplifies the company’s capital structure ahead of potential commercialization of its pipeline. ABIVAX, listed as ENXTPA:ABVX, focuses on developing therapies in the biopharma space, where funding structures and future payment obligations can be...

Clariane (ENXTPA:CLARI) has drawn fresh attention after completing a €232.875 million fixed income offering of 6.875% senior notes due 2031, aimed at refinancing higher coupon hybrid green perpetual bonds. See our latest analysis for Clariane. The new refinancing has arrived alongside stronger recent trading, with a 1-month share price return of 10.05% and a 1-year total shareholder return of 13.54%, although the 5-year total shareholder return decline of 76.97% shows longer term holders have...

In April 2026, Teleperformance announced a three-year contract with ScotRail to run customer contact centre services from Glasgow and remote teams across Scotland, initially covering voice, email, messaging and whitemail with support from UP3’s ServiceNow platform. This win deepens Teleperformance’s presence in UK transportation services, adding ScotRail to an existing roster of rail clients and broadening sector diversification. We’ll now examine how this ScotRail contract, which expands...

Considering whether Danone at €62.80 is beginning to offer value, or if the stock still carries too much optimism in its price. The share price has retreated recently, with a 5.9% decline over the last week, a 9.0% decline over the last month, and a 17.4% decline year to date. This is despite a 29.0% return over five years and 17.3% over three years. Recent headlines have focused on Danone's broader positioning in the global food and beverage sector and how it is responding to changing...

Recent performance snapshot Robertet (ENXTPA:RBT) has been on many watchlists after a year to date share price decline of about 10%, accompanied by negative returns over the past month and the past 3 months. See our latest analysis for Robertet. The 10.47% year to date share price decline, alongside a 12.35% fall in the 5 year total shareholder return, points to fading momentum as the market reassesses Robertet's growth outlook and risks. If you are comparing Robertet with other opportunities...

A lackluster earnings announcement from MGI Digital Technology Société Anonyme ( EPA:ALMDG ) last week didn't sink the...

If you are wondering whether EssilorLuxottica Société anonyme is attractively priced right now, starting with a clear view of its current valuation can help you frame that decision. The stock last closed at €171.40, with recent returns showing a 5.4% decline over 7 days, a 14.6% decline over 30 days, a 35.4% decline year to date, and a 27.6% decline over the past year, compared with a 35.5% return over 5 years. Recent coverage around EssilorLuxottica Société anonyme has focused on its role...

The subdued market reaction suggests that Crosswood SA's ( EPA:CROS ) recent earnings didn't contain any surprises...

A lackluster earnings announcement from Bilendi SA ( EPA:ALBLD ) last week didn't sink the stock price. However, we...

Key recent performance snapshot Engie (ENXTPA:ENGI) has drawn attention after a recent 0.5% daily gain, contrasted with a 3.8% decline over the past week and a 6.6% decline over the past month, despite a 5% gain in the past 3 months. For longer term holders, the stock shows a 17.5% return year to date and a 57.6% total return over the past year, with multi year total returns above 100%. This performance may prompt some investors to reassess their exposure. See our latest analysis for...

Ramsay Générale de Santé (ENXTPA:GDS) has reported H1 2026 revenue of €2.6b and a basic EPS loss of €0.31, with net income excluding extra items at a loss of €33.3m. The trailing twelve months show revenue of €5.3b and a basic EPS loss of €0.38 tied to a €41.2m net loss. Over recent halves, revenue has moved from €2.5b in H1 2025 to €2.6b in H1 2026. Basic EPS has remained in loss-making territory, ranging from a €0.39 loss in H1 2025 to a €0.33 loss in H2 2024 and a €0.31 loss in H1 2026,...

What recent performance suggests about ID Logistics Group ID Logistics Group (ENXTPA:IDL) has seen mixed share performance recently, with the stock down about 1.7% on the day and 3.3% over the past week, but slightly positive over the past month. Over the past 3 months, the stock shows a decline of around 14%, and the year to date return is roughly 13% lower, while the 1 year total return is also about 14% lower. See our latest analysis for ID Logistics Group. With the share price at...

Italian unions have called a strike targeting Kering in response to a reorganization plan and layoffs at Alexander McQueen. The action is focused on the group’s Italian operations, where many key activities in the luxury supply chain are based. The dispute highlights tensions between Kering’s restructuring efforts and worker concerns over job security and working conditions. The strike comes at a time when Kering, traded as ENXTPA:KER, is under close watch from investors. The share price...

Sanofi (ENXTPA:SAN) has been named the inaugural industry sponsor of the AlphaDetect initiative to advance early detection of Alpha-1 Antitrypsin Deficiency. The company is also working with Maze Therapeutics to improve Pompe disease outcomes through the use of Nexviazyme. These partnerships focus on rare respiratory and metabolic diseases, with an emphasis on earlier diagnosis and patient management. For readers tracking ENXTPA:SAN, these moves sit within Sanofi’s rare disease and...

As European markets navigate the complexities of stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index remains relatively stable, reflecting a cautious yet resilient economic environment. In this context, dividend stocks can offer investors a potential source of steady income and stability, particularly when broader market conditions are uncertain.

Legrand (ENXTPA:LR) has kicked off 2026 with Q1 revenue of €2.5b and basic EPS of €1.28, setting the tone for investors focused on how its earnings profile is evolving. Over the last year, the company has seen trailing twelve month revenue move from €8.6b to €9.7b and basic EPS lift from €4.45 to €4.91, giving you a clear sense of how the top and bottom lines have been tracking into this latest quarter. With net profit margins broadly steady, the focus now is on how these results align with...

It's been a good week for STMicroelectronics N.V. ( EPA:STMPA ) shareholders, because the company has just released its...

Arkema (ENXTPA:AKE) opened 2026 with Q1 revenue of €2.2b and basic EPS of €0.36, as investors weigh these fresh numbers against a trailing 12 month EPS of €0.23 on €8.9b of revenue and a net income of €17m that reflects thin profitability. Over the last year, a reported net profit margin of 0.2% and a large one off loss in the trailing figures have kept earnings in focus, while analysts in the dataset still see scope for earnings growth ahead. Overall, the latest quarter keeps attention...

Optimism over a potential resolution to the Middle East conflict is lifting expectations for international travel and luxury spending. This improved sentiment is feeding through to Hermès International Société en commandite par actions (ENXTPA:RMS) and the wider European luxury sector. Investors are reassessing demand prospects for high-end goods as travel dependent spending comes back into focus. Hermès shares last closed at €1,671.5, with the stock up 4.0% over the past week but showing...

If you are wondering whether L'Oréal's current share price reflects its true worth, you are not alone, especially with valuation tools often sending mixed signals. The stock most recently closed at €373.40, with returns of 2.1% over the past week, 4.2% over the past month, 2.4% year to date, 1.7% over 1 year, negative 5.7% over 3 years, and 16.9% over 5 years. Recent coverage of L'Oréal has focused on its position as a global beauty leader and how it is adapting product lines and marketing...